Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab

Kristin Skougaard, Dorte Nielsen, Benny Vittrup Jensen, Helle Westergren Hendel

73 Citationer (Scopus)

Abstract

The study aim was to compare European Organization for Research and Treatment of Cancer (EORTC) criteria with PET Response Criteria in Solid Tumors (PERCIST) for response evaluation of patients with metastatic colorectal cancer treated with a combination of the chemotherapeutic drug irinotecan and the monoclonal antibody cetuximab.
OriginalsprogEngelsk
TidsskriftJournal of nuclear medicine : official publication, Society of Nuclear Medicine
Vol/bind54
Udgave nummer7
Sider (fra-til)1026-31
Antal sider6
ISSN0161-5505
DOI
StatusUdgivet - jul. 2013

Fingeraftryk

Dyk ned i forskningsemnerne om 'Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab'. Sammen danner de et unikt fingeraftryk.

Citationsformater